Medtronic evolut™ tavr system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

Galway, ireland and chicago , march 30, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the evolut low risk trial. data shows, versus surgery, the evolut™ transcatheter aortic valve replacement (tavr) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes.
MDT Ratings Summary
MDT Quant Ranking